- Report
- January 2026
- 120 Pages
Global
From €4264EUR$4,750USD£3,651GBP
- Report
- May 2026
- 150 Pages
Global
From €2423EUR$2,699USD£2,074GBP
- Report
- April 2026
- 150 Pages
Global
From €2692EUR$2,999USD£2,305GBP
€3590EUR$3,999USD£3,073GBP
- Report
- July 2026
- 130 Pages
Global
From €4264EUR$4,750USD£3,651GBP
- Report
- April 2026
- 180 Pages
Global
From €4264EUR$4,750USD£3,651GBP
- Report
- April 2026
- 160 Pages
Global
From €2980EUR$3,320USD£2,552GBP
€3726EUR$4,150USD£3,189GBP
- Report
- October 2025
- 160 Pages
Global
From €2837EUR$3,160USD£2,429GBP
€3546EUR$3,950USD£3,036GBP
- Report
- October 2025
- 160 Pages
Global
From €2837EUR$3,160USD£2,429GBP
€3546EUR$3,950USD£3,036GBP
- Report
- October 2025
- 160 Pages
Global
From €2837EUR$3,160USD£2,429GBP
€3546EUR$3,950USD£3,036GBP
- Report
- October 2025
- 160 Pages
Global
From €2837EUR$3,160USD£2,429GBP
€3546EUR$3,950USD£3,036GBP
- Report
- August 2025
- 150 Pages
Global
From €4354EUR$4,850USD£3,727GBP
- Report
- April 2026
- 91 Pages
Global
From €3500EUR$4,176USD£3,101GBP
- Report
- April 2026
- 99 Pages
Global
From €3500EUR$4,176USD£3,101GBP
- Report
- September 2025
- 112 Pages
Global
From €3500EUR$4,176USD£3,101GBP
- Report
- September 2025
- 140 Pages
Global
From €4354EUR$4,850USD£3,727GBP
- Report
- March 2026
- 107 Pages
Asia Pacific
From €3546EUR$3,950USD£3,036GBP
- Report
- March 2026
- 104 Pages
Europe
From €3546EUR$3,950USD£3,036GBP
- Report
- March 2026
- 88 Pages
North America
From €3097EUR$3,450USD£2,651GBP
- Report
- May 2025
- 100 Pages
Global
From €5341EUR$5,950USD£4,573GBP
- Report
- November 2024
- 100 Pages
Global
From €5341EUR$5,950USD£4,573GBP

Adalimumab is a biologic drug used to treat a variety of immune disorders, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Adalimumab is administered by subcutaneous injection and is available in both brand-name and generic forms.
Adalimumab is one of the most widely prescribed drugs for immune disorders, and it has been approved for use in more than 100 countries. It is a highly effective treatment for many of the conditions it is used to treat, and it has been shown to improve quality of life for patients.
Some of the companies in the Adalimumab market include AbbVie, Amgen, Biogen, Boehringer Ingelheim, Janssen Biotech, Merck, and Pfizer. Show Less Read more